IBA SA - basic data - update following capital increase dated 21 April 2017
21 Avril 2017 - 11:00AM
IBA - DATA
CONCERNING TRANSPARENCY
Heading II of the law of May 2, 2007 and the Royal
Decree of February 14, 2008
Louvain-la-Neuve,
Belgium, April 21, 2017, 11 a.m. - IBA (Ion Beam Applications
SA), the world's leading provider of proton therapy solutions for
the treatment of cancer, communicates today the basic and
additional data as per Article 15 §1 al.1 of the Transparency Law,
following its capital increase (further to exercises of stock
options) dated April 21, 2017.
Communication of the basic data as per Article 15
§1 al.1 of the Law
-
Total capital:
EUR 41 899 278.10
-
Total number of securities conferring the voting
right:
29 852 549 (of which 12 702 489 with VVPR
strips)
-
Total number of voting rights (= the
denominator):
29 852 549
-
Total number of securities conferring the voting
right, by category: N/A
-
Total number of voting rights, by
category:
N/A
Communication of the additional data as per
Article 15 §1 al.2 of the Law
-
Total number of convertible bonds conferring the
voting right:
0
-
Total number of rights, materialized or not by
certificates, giving the
right to subscribe to newly issued securities conferring the voting
right
(e.g.
warrants):
509 850
-
Total number of voting rights which would result
from the exercise of
these conversion or subscription
rights:
509 850
-
Total number of shares without voting right:
0
Statutory thresholds as per Article 18 of the
Law
The applicable thresholds as
follows: three percent, five percent, ten percent, fifteen percent
and so on by brackets of five percent
About
IBA
IBA (Ion Beam Applications S.A.) is a global medical technology
company focused on bringing integrated and innovative solutions for
the diagnosis and treatment of cancer. The company is the worldwide
technology leader in the field of proton therapy, considered to be
the most advanced form of radiation therapy available today. IBA's
proton therapy solutions are flexible and adaptable, allowing
customers to choose from universal full-scale proton therapy
centers as well as compact, single room solutions. In addition, IBA
also has a radiation dosimetry business and develops particle
accelerators for the medical world and industry. Headquartered in
Belgium and employing about 1,500 people worldwide, IBA has
installed systems across the world.
IBA is listed on the pan-European
stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg
IBAB.BB). More information can be found at:
www.iba-worldwide.com
For further
information, please contact:
IBA
Caroline
Hardy
Corporate Legal Counsel
+32 10 201 159
caroline.hardy@iba-group.com
20170421 evolution of the basic
data EN
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: IBA SA via Globenewswire
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024